11/21
05:04 pm
lctx
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering [Yahoo! Finance]
High
Report
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering [Yahoo! Finance]
11/21
05:00 pm
lctx
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
High
Report
Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
11/21
11:28 am
lctx
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
Low
Report
Lineage Cell (LCTX) Loses -26.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner [Yahoo! Finance]
11/20
08:22 am
lctx
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering [Yahoo! Finance]
High
Report
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering [Yahoo! Finance]
11/20
08:00 am
lctx
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
High
Report
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
11/14
04:01 pm
lctx
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/7
08:00 am
lctx
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Low
Report
Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
10/14
08:00 am
lctx
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
Low
Report
Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
9/25
08:00 am
lctx
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
Medium
Report
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium